Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Abstract Text:

Francoise Fougerousse,Marc Bartoli, Poupiot,Ludovic Arandel,Muriel Durand,Nicolas Guerchet,Evelyne Gicquel,Olivier Danos,Isabelle Richard,Francoise Fougerousse,Marc Bartoli, Poupiot,Ludovic Arandel,Muriel Durand,Nicolas Guerchet,Evelyne Gicquel,Olivier Danos,Isabelle Richard,

alpha-Sarcoglycanopathy (limb-girdle muscular dystrophy type 2D, LGMD2D) is a recessive muscular disorder caused by deficiency in alpha-sarcoglycan, a transmembrane protein part of the dystrophin-associated complex. To date, no treatment exists for this disease. We constructed recombinant pseudotype-1 adeno-associated virus (rAAV) vectors expressing the human alpha-sarcoglycan cDNA from a ubiquitous or a muscle-specific promoter. Evidence of specific immune response leading to disappearance of the vector was observed with the ubiquitous promoter. In contrast, efficient and sustained transgene expression with correct sarcolemmal localization and without evident toxicity was obtained with the muscle-specific promoter after intra-arterial injection into the limbs of an LGMD2D murine model. Transgene expression resulted in restoration of the sarcoglycan complex, histological improvement, membrane stabilization, and correction of pseudohypertrophy. More importantly, alpha-sarcoglycan transfer produced full rescue of the contractile force deficits and stretch sensibility and led to an increase of the global activity of the animals when both posterior limbs are injected. Our results establish the feasibility for AAV-mediated alpha-sarcoglycan gene transfer as a therapeutic approach.Molecular Therapy (2007) 15, 53-61. doi:10.1038/sj.mt.6300022.

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Publishing Authors By Initials

F Fougerousse,M Bartoli,J Poupiot,L Arandel,M Durand,N Guerchet,E Gicquel,O Danos,I Richard,F Fougerousse,M Bartoli,J Poupiot,L Arandel,M Durand,N Guerchet,E Gicquel,O Danos,I Richard,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Molecular therapy : the journal of the American So

VOLUME: 15

Page Numbers: 53-61

Journal Abbreviation: Mol. Ther.

ISSN: 1525-0016

DAY: 13

MONTH: Jan

YEAR: 2007

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100890581

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.

AFFILIATION: 1Généthon, CNRS UMR8115, 1 rue de l'Internationale, Evry, France.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector Related Publications

• A novel GJA 1 mutation in oculo-dento-digital dysplasia with curly hair and hyperkeratosis.
• A simple method to determine kinetic deuterium isotope effects provides evidence that proton transfer to carbon proceeds over and not through the reaction barrier.
• A transition state analog for phosphate diester cleavage catalyzed by a small enzyme-like metal ion complex.
• An optimised methodology for the neurobehavioural assessment in rodents.
• Claisen-type addition of glycine to a pyridoxal iminium ion in water.
• Coming out to care: caregivers of gay and lesbian seniors in Canada.
• Covalent catalysis by pyridoxal: evaluation of the effect of the cofactor on the carbon acidity of glycine.
• Dissection of a genetic locus influencing renal function in the rat and its concordance with kidney disease loci on human chromosome 1q21.
• Energy expenditure: a critical determinant of energy balance with key hypothalamic controls.
• Enzymatic catalysis of proton transfer at carbon: activation of triosephosphate isomerase by phosphite dianion.
• Foamy Virus Vectors Expressing Anti-HIV Transgenes Efficiently Block HIV-1 Replication.
• Identification in the mould Hypocrea jecorina of a gene encoding an NADP(+): d-xylose dehydrogenase.
• Improvement of VO2max by cardiac output and oxygen extraction adaptation during intermittent versus continuous endurance training.
• Inhibition of humic substances mediated photooxygenation of furfuryl alcohol by 2,4,6-trimethylphenol. Evidence for reactivity of the phenol with humic triplet excited states.
• Malignant proliferating pilar tumors arising in KID syndrome: a report of two patients.
• Phenotypic Correction of alpha-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.
• Practical identifiability of photophysical parameters in photodynamic therapy.
• Product deuterium isotope effect for orotidine 5'-monophosphate decarboxylase: evidence for the existence of a short-lived carbanion intermediate.
• Rational design of transition-state analogues as potent enzyme inhibitors with therapeutic applications.
• Some major mycotoxins and their mycotoxicoses-An overview.
• Targeting the RNA-binding protein Sam68 as a treatment for cancer?
• The motivational interview.
• The motivational interview: In practice.
• Topical tacrolimus treatment for chronic dermatitis of the ear.
• Use of local area facilities for involvement in physical activity in Canada: insights for developing environmental and policy interventions.
• When does an intermediate become a transition state? Degenerate isomerization without competing racemization during solvolysis of (S)-1-(3-nitrophenyl)ethyl tosylate.
• Winning the battle for standardization. The U.S. Army Medical Department examines the EMR to develop a standardized process for medication reconciliation documentation.
• [Carbon dioxide laser therapy for anogenital warts in children.]
• [The lessons of Cleopatra or reflections on conter-transfer and borderlines.]
• [The prevalence of bilateral malignant uveal melanoma]